Renal diseases are associated with a variety of haemopoietic changes. Anaemia parallels the degree of renal impairment and its most important cause is failure of renal erythropoietin secretion. Other factors include depressed red cell production and reduced red cell survival. Purpura and bleeding are predominantly due to platelet dysfunction and usually respond to dialysis. Cryoprecipitate and I-deamino-B-d-arginine vasopressin may be of value in the bleeding patient. Abnormal coagulation with fibrin deposition in the microcirculation is now recognised as a mechanism of renal impairment. Plasma infusion and anticoagulants may be useful in the therapy of conditions in which this occurs. Plasma exchange is now used in the investigation and management of some varieties of immunologically mediated renal disease. Blood transfusion has been found to improve graft survival if given prior to renal transplantation and this effect is currently under active investigation.
It has long been recognised that patients with renal disease have alterations in their haemopoietic status. Pallor and easy bruising are common presenting manifestations of chronic renal failure. Bleeding and infection are common modes of death in untreated renal failure. Recent research has provided more information on the pathogenesis and management of these problems.
The deposition of fibrin in the kidneys is now thought to be a mechanism of renal impairment in some disorders. Thus abnormal coagulation, whether generalised or occurring only in the renal microcirculation, may be made manifest by renal failure.
Finally, manipulation of the blood by transfusion therapy or by apheresis is providing new avenues of management and investigation in patients with selected renal diseases. 
ANAEMIA AND RENAL FAILURE Degree and pathophysiology
There is a rough linear relationship between anaemia and renal impairment at blood urea nitrogen levels of less than 150 mg/100 m!. A similar relationship exists between the haematocrit and creatinine clearance. With further deterioration of renal function the haematocrit stabilises between 30070 and 15%. 1 In renal failure the degree of anaemia may be exaggerated or minimised by fluid retention and dehydration causing fluxes in plasma volume.
The red cells are usually normocytic and normochromic with occasional acanthocytes and fragmented cells. Burr cells are now considered nonspecific. 2 Reticulocytes are present but the numbers do not correlate with the degree of anaemia. Thus, the major pathogenetic factor in the anaemia of chronic renal failure is failure of the bone marrow to produce adequate numbers of red cells. 3 The important factor leading to impaired erythropoiesis is failure of the renal erythropoietin-secreting mechanism relative to the increased demand. Erythropoietin is a glycoprotein that is produced mainly by the kidney. Extra-renal production has been demonstrated by in vitro cultures of foetal liver, bone marrow and splenic macrophages. 4 Erythropoietin tagged with fluorescein will concentrate in the glomeruli but the exact site of synthesis is unknown. Plasma erythropoietin levels in patients undergoing long-term haemodialysis, although inappropriately low for the degree of anaemia, are still initially higher than normal. 5, 6 The renal endocrine function, however, deteriorates in parallel with renal function. It is of interest to note that renal transplant rejection has been associated with increased erythropoietin levels and secondary polycythaemia demonstrating that a normal bone marrow response to erythropoietin stimulation is possible.
In addition to erythropoietin deficiency, other factors may depress erythropoiesis. Substances, partially removable by haemodialysis, have been found in uraemic serum, which will inhibit the growth of erythroid stem cells in cultures. 7 The number of erythroid colonies formed and the in vitro sensitivity of erythroid progenitors to exogenous androgens correlates with a clinical response to androgen therapy. 8 Uraemic toxins in the middle molecular weight range are thought to interfere with bone marrow function. Continuous ambulatory peritoneal dialysis (CAPD) is more effective in removing these and normalisation of haematocrit with this form of dialysis has been reported. 9 Parathyroid hormone has also been postulated to be a uraemic toxin contributing to the anaemia of chronic renal failure and has been shown to suppress in vitro erythroid colony growth. Some improvement in the haematocrit has been observed after parathyroidectomy. to It has been suggested in uraemic patients with severe hyperparathyroidism that the bone marrow is less responsive to erythropoietin. 5 The second pathogenetic factor in the anaemia of chronic renal failure is reduced red cell survival which averaged 66 (range 30-100; normal 120) days in 13 patients on haemodialysis. ll No improvement was noted over a 3-year period of dialysis. 12 There is no direct relationship, however, between increasing uraemia and reduced red cell viability. Cross-transfusion studies have shown normal survival of "uraemic" red cells in healthy recipients and reduced survival of normal cells in uraemic patients. 13 Increased levels of guanidine and methylguanidine have been postulated to cause the haemolysis, 14 however, the exact nature of the extracorpuscular haemolytic factor remains unknown.
Numerous red cell metabolic abnormalities have been reported in chronic renal failure. 15 The effects of these changes are difficult to resolve but the result may be an alteration in the oxygen affinity of haemoglobin or an alteration in the sensitivity of the red cell to oxidant stresses (due to reduced red cell glutathione stability). This may be induced by drugs or chemicals. Acidosis will initially shift the haemoglobin-oxygen (Hb-02) dissociation curve to the right, increase the P 5 0 and improve tissue oxygen delivery. The associated decreased glycolysis and impaired 2,3-diphosphoglycerate (2,3-DPG) production counters the beneficial effects and shifts the Hb-02 dissociation curve back to the left. Marked acidosis in chronic renal failure is the predominant factor influencing red cell metabolism and thereby Hb-0 2 affinity. 16 It has been suggested that post-dialysis symptoms may be related to sudden reduction of the P 50 by rapid correction of the acidosis with a left shift in the Hb-02 dissociation curve, before a compensatory rise in 2,3-DPG has time to occur. Long-term oral bicarbonate to prevent acidosis (in patients who can tolerate the increased sodium load) increases levels of 2,3-DPG and shifts the Hb-0 2 curve and the P 50 to the right thus improving tissue oxygenation. 17 
Contributing causes
The underlying renal disease or its management may lead to deficiencies compounding the anaemia of renal disease. Iron loss related to bleeding from the gastrointestinal tract, and blood loss in the dialysis coil or associated with laboratory testing, has been calculated to be 1-2 mg/day in excess of normal losses and may easily result in Anaesthesia and Intensive Care, Vol. ll, No. 4, November, 1983 iron deficiency anaemia. 18 Several series have shown a good correlation between the serum ferritin concentration and bone marrow iron stores in patients with chronic renal failure and those on maintenance haemodialysis. 19 It is a useful parameter of iron status provided that, as in chronic inflammatory disorders, the lower limit of normal is adjusted slightly upwards. Folate and pyridoxine deficiency, tentatively related to loss in the dialysate, may also contribute to the anaemia. 20 Haemolysis may be caused or aggravated by mechanical trauma, as in the microangiopathic haemolytic anaemias. "Epidemics" of Heinz body mediated haemolytic anaemias related to increased oxidant stresses on the red cell are occasionally seen in dialysis units and have been attributed to excess chloramines,21 copper 22 and nitrates. 23 
Management
In asymptomatic patients no therapy is required for the anaemia. However, transfusion is often necessary as renal impairment progresses. The question of blood transfusion and HLA sensitisation prior to renal transplantation is considered later in this review. It is essential that all treatable causes that could contribute to the anaemia be excluded. Supplementation with iron, folic acid, pyridoxine and ascorbic acid has been used extensively and empirically. 3, 13 Several controlled studies of patients on maintenance haemodialysis have shown the value of androgens as an adjuvant to therapy. Increased haematocrit and exercise tolerance with corresponding decrease in transfusion requirements have been reported. 3 ,18,13 Sideeffects of masculinisation and hepatic dysfunction can, however, be disconcerting. Androgens act by stimulating erythropoiesis directly and by increasing renal, and to a lesser extent extrarenal, production of erythropoietin, The use of exogenous erythropoietin may eventually be the treatment of choice; however, only small amounts are available and only as impure preparations.
HAEMOSTASIS IN RENAL DISEASE
It is well known that patients with chronic renal failure have a bleeding tendency. Clinical bleeding may be severe and ecchymoses and gastrointestinal bleeding are frequent. Haemorrhage may also occur into muscles and Anaesthesia and Intensive Care, Vol. 11, No. 4, November, 1983 serous cavities. In untreated renal failure bleeding is a common cause of death.2~ However, the extent of the haemostatic impairment varies considerably from patient to patient and this raises problems for the surgeon and anaesthetist in assessing the likely blood requirements in individual patients.
Platelet dysfunction
The haemostatic defect in uraemia is complex but the most consistent and important abnormality is qualitative platelet dysfunction. 24 ,25 The best clinical test to assess this appears to be the skin bleeding time and this best discriminates between bleeding and non-bleeding patients. 26 Defects in laboratory tests of platelet function are inconsistent but the basic defect appears to be in the release reaction during which platelets release ADP causing secondary aggregation. There is also deficient aggregation to adrenaline, collagen and ADP. Platelet factor III activity is usually reduced and platelet retention is impaired. 27 There is good evidence that these abnormalities are in part produced by a dialyzable factor but the exact nature of the responsible factor remains controversial. 27 Urea, guanidosuccinic acid and various phenols have been implicated. 28 Hypermagnesaemia may also be important. 29 More recently abnormalities of prostaglandin synthesis have been described. Prostaglandin metabolites of aracadonic acid are now thought to play a major role in normal haemostasis and some thrombotic disorders. Prostacyclin is produced in the vessel walls. It is vasodilatory and is a potent inhibitor of platelet aggregation. Thromboxane A2 is produced in platelets and is a potent vasoconstrictor which aggregates platelets. Production of prostacyclin in venous tissue from uraemic patients is increased and still present ex vivo after repeated washings. 30 This suggests that prostacyclin may be a nondialysable factor contributing to the haemorrhagic diathesis of uraemia. Production of prostaglandins in platelets as measured by malondialdehyde excretion has been found to be reduced. 31 Production of thromboxane A2 was also found to be reduced in uraemic platelets. 32 The relationship between uraemia and abnormalities in prostaglandin synthesis and its importance in causing clinical bleeding remains to be clarified.
Coagulation
As well as the platelet defect, there are abnormalities in the coagulation system in renal disease. Changes in factor VIII concentration are the most consistent and probably the most important. One of the paradoxes of chronic renal failure is that accelerated atherogenesis occurs despite the prolonged bleeding time and abnormal platelet function. 33 This may be explained by the significantly raised factor VIII concentration and increased fibrinogen concentration. 34 The ratio of factor VIIIrelated antigen to factor VlII-procoagulant activity is also increased with increased concentrations of factor VIII -von Willebrand factor. 35 The concentration of antithrombin III is reduced. 36 In summary there appears to be prothrombotic state in chronic renal failure, particularly in those patients on regular dialysis.
The nephrotic syndrome is a particular case in which both venous and arterial thrombotic events occur. In these patients, various clotting factors are increased in concentration, antithrombin III levels are depressed and platelets have increased aggregability.37 This is probably on the basis of increased synthesis of thromboxane A2.
Management
As far as the practising clinician is concerned, the bleeding time appears to offer the best guide to the haemostatic state. The incidence of serious haemorrhage has been greatly diminished in recent years because of more intensive dialysis and the avoidance of anti-platelet drugs such as aspirin. Dialysis provides the best prophylaxis against bleeding during operative procedures. In the bleeding patient who has not responded to dialysis or in whom the situation is critical, platelet transfusion should be considered although the effect would be very transient. Prelimary information suggests that cryoprecipitate 39 and I-deamino-8-d-arginine vasopressin 40 may shorten the bleeding time and may be effective in controlling major bleeding. The reasons for this are uncertain and these results need to be confirmed.
ABNORMAL COAGULATION IN THE PA THOGENESIS OF RENAL DISEASE
Abnormal deposition of fibrin in glomeruli and other parts of the renal microcirculation may be a factor in a variety of diseases resulting in renal failure.
Haemolytic Uraemic Syndrome (HUS) and Thrombotic Thrombocytopenic Purpura (TTP)
HUS and TTP are both associated with acute severe damage to small blood vessels. Clinically they merge but there are some important differences. In TTP the damage is widespread and patients present with fever, neurological signs, renal failure, haemolytic anaemia, and thrombocytopenia. 41 In HUS glomerular capillaries are the major site of vascular injury and renal failure and haemolytic anaemia are the presenting features.
The pathogenesis of these diseases is illunderstood but an abnormal plasma factor has been described in TTP which causes aggregation of platelets. 41 There is no doubt that focal intravascular coagulation contributes to vascular injury with deposition of fibrin in the microcirculation.
Plasma infusions are generally used in the treatment of TTP and occasionally plasma exchange and anti-platelet agents are tried. Corticosteroids, splenectomy and immunosuppressive drugs have also been used. 42 The effect of plasma infusions in HUS is uncertain but heparin, fibrinolytic agents and plasma exchange have been used with limited success.
Disseminated Intravascular Coagulation (DIC)
This is a multifactorial disorder with breakdown of haemostasis leading to haemorrhage and obstruction of the microcirculation by fibrin. Fibrin deposits are observed more frequently in the kidney than other organs and this may be because the kidney with its rich microcirculation acts as a sieve. Clinically, renal failure is a common complication of DIC, particularly the chronic variety. The management of DIC is always directed to the underlying disease. However, low-dose heparin and infusion of human antithrombin III has been used to prevent microthrombosis.
PLASMA EXCHANGE
In recent years, the development of sophisticated cell separator machines has led to an expansion of the use of plasma exchange in the treatment and investigation of a variety of diseases. This technology has been applied with some success in a variety of immunologically mediated renal disease.
Anti-glomerular basement membrane disease
This disease is characterised by rapidly progressive glomerulonephritis and lung haemorrhage. It is often associated with the presence of anti-glomerular basement membrane antibodies and linear immunofluorescent staining for IgG on renal glomerular and pulmonary alveolar basement membranes. A number of studies have shown intensive plasma exchange to be of value in those patients with active lung haemorrhage and active nephritis. 43 However, a controlled clinical trial using this form of therapy has not been adequately performed.
Rapidly progressive glomerulonephritis
This disease, generally associated with systemic vasculitis, is thought to be related to deposition of immune complexes in the kidney. Plasma exchange has not been as clearly successful in this group and further controlled trials are required. 43
Renal transplant rejection
Despite initial encouraging results renal transplant rejection shows no lasting benefit from plasma exchange. 44 Any short-term effect may be due to depletion of the mediators of inflammation such as complement and fibrinogen. Lymphocytapheresis may offer some additional hope.
BLOOD TRANSFUSION

Transfusion reactions
The most dramatic interface between haematology and renal medicine is the major haemolytic transfusion reaction. This usually occurs because of the transfusion of incompatible red cells resulting in intravascular lysis with haemoglobinaemia. Rarely it can result from the infusion of a high titre haemolysin in the plasma of transfused blood.
Antibody-mediated intravascular lysis occurs only with those antibodies which activate the whole complement sequence. Virtually all strongly lytic red cell alloantibodies have the Anaesthesia and Intensive Care, Vol. 11, No. 4, November, /983 specificity anti-A or anti-B. This means that ABO incompatibility is the most important cause of renal failure and death from blood transfusion. 45 A recent analysis of deaths reported to the Food and Drug Administration in the United States documented 113 fatalities. This was in a 45-month period between 1976 and 1979 with a fatality rate of 0.00023070. Of these, 30070 were due to post-transfusion hepatitis and 68070 were due to transfusion reactions. Of the transfusion reactions, 61070 were due to "clerical errors", i.e. wrong sample, wrong patient, etc. Group 0 recipients were most at risk and constituted 77070 of the fatalities. The operating room is a particularly dangerous place because the patient cannot be identified verbally and cannot check his own transfusion. In addition, the signs and symptoms of a transfusion reaction are masked by anaesthesia. 45 In half of the operating room fatalities reported to the FDA, blood had been stored in an operating room refrigerator rather than the Blood Bank. The report suggested that this was a dangerous practice. 46 The symptoms and signs of a major haemolytic transfusion reaction are well known and include sternal and lumbar pain, flushing of the face, hypotension and bleeding. These reactions cause death by producing acute renal failure or uncontrollable bleeding secondary to disseminated intravascular coagulation. 45 The cause of the renal failure is incompletely understood but is probably multi-factorial with hypotension, disseminated intravascular coagulation and the nephrotoxic effects of free red cell stroma involved. Immune mechanisms are also very important in the generation of DIe and renal failure.
Renal transplantation
Blood transfusion, once thought to have an adverse effect on the outcome of renal transplantation, has recently been found to provide strikingly beneficial effects.47 Many groups have demonstrated improved graft survival with blood transfusion in cadaveric renal transplantation. 48 However, there is a lack of consensus on the optimum protocol for its use. Debate continues on whether transfusions given at the time of transplant are as effective as those given prior to transplant. The ideal blood component is also unclear but the presence of leucocytes appears to be important. 49 More recent protocols include the use of donor-specific transfusions to induce specific allograft tolerance. 48 The mechanisms for this effect are being investigated but alteration of reticulo-endothelial function and increase in suppressor T-cell activity have been proposed. 50
Serological problems
Haemodialysis patients have an unexpectedly high incidence of anti-N-like antibodies. These are cold antibodies active against an antigenic site on red cells. 51 This phenomenon only occurs in patients who use formalin-sterilised dialysers and is thought to be due to formalin denaturation of the MN antigen site. From the clinical viewpoint, these antibodies are only likely to cause problems in crossmatching and there is no evidence that they cause in vivo haemolysis. However, there has been a case in which the antibody was held responsible for the rejection of a chilled transplanted kidney. 51
LEUCOCYTES AND RENAL DISEASE
In uncomplicated renal failure the leucocyte count is usually normal although eosinophilia has been reported. 52 Within the first few minutes of haemodialysis, transient granulocytopenia develops. This is related to a marked increase in granulocyte adherence as the cells marginate in the pulmonary circulation and is thought to be mediated by complement components activated by the dialysis coil. 53 A similar mechanism of complement-mediated leucocyte aggregation is thought to contribute to the genesis of the adult respiratory distress syndrome. 54 Hypoxaemia is noted during haemodialysis and may have important clinical correlates. It is thought to be related to complement-mediated pulmonary leukostasis resulting in a ventilation-perfusion mismatchY Hakin and Lowrie report that within the first hour of dialysis the leucopenia and hypoxaemia are dependent on the type of membrane used. In the latter stages of dialysis hypoventilation (related to a reduction in CO 2 production and occurring only with acetate dialysis) is superimposed upon and persists after resolution of the pulmonary leukostasis. 56 In dialysis patients hypoxaemia is associated with a fall in systolic blood pressure with no compensatory increase in heart rate or cardiac contractility and is preventable with the use of 40070 oxygen. 57 . 58 Many changes in neutrophil function have been documented in these patients including inhibition of chemotaxis, phagocytosis, and decreased random mobility. 15 The variation in the number and function of neutrophils with each dialysis, the decreased chemotactic responsiveness of neutrophils and the depressed immune system may well contribute to the high rate of infection in haemodialysed patients. The mechanisms for this immunosuppression, however, are not known. There is a marked variability in T -and B-cell function between individuals despite normal numbers of lymphocytes. Depressed T -cell mediated responses and immunosuppressive serum factors have been well documented. 59 Perhaps the variability may be attributed to differences in age, nutritional status, presence of infection or to the underlying renal disease and its specific therapy. CONCLUSION In this review we have outlined the changes in the haemopoietic system induced by renal disease. Anaemia and acidosis reduce tissue oxygenation. Changes in neutrophil function and depression of the immune system contribute to the increased susceptibility to infection. The alteration in platelet function results in a haemostatic disturbance despite the fact that many patients have accelerated vascular disease. These changes need to be carefully evaluated in patients in whom anaesthesia or an operative procedure is contemplated.
Haemopoietic manipulation by transfusion therapy or apheresis has become an important therapeutic measure in some patients. The effects of blood transfusion in renal transplantation is an exciting area requiring further study.
